Achieving optimal doses in treatment of heart failure with reduced ejection fraction At Nhan dan Gia Dinh Hospital
DOI:
https://doi.org/10.58354/jvc.107E.2023.710Tóm tắt
Heart failure (HF) with reduced ejection fraction (HFrEF) is a complex clinical syndrome associated with high mortality, long hospital length of stay, high readmission rates, reduced exercise tolerance, and decreased quality of life, as well as requiring significant resources to support treatment and care 1. Currently, it is reported that approximately 50% of all heart failure cases are HFrEF. However, due to recent advancements in cardiovascular diagnostic imaging, earlier, and possibly more precise, detection of HFrEF is greatly enabled. Not only does this seemingly increase the incidence rate of HfrEF in the general population, but it also gives treatment facilities an advantage in improving the prognosis and average life expectancy for these newly rising cases of HFrEF 2. According to heart failure treatment guidelines by Heart Associations around the world, an effective, interdisciplinary, and coordinated care system needs to be applied to all heart failure patients, including the reduced ejection fraction heart failure group, in order to achieve optimal guidelinesrecommended therapy, reduce mortality and readmission. In addition, each patient needs to be provided with a detailed treatment plan, which comprises treatment goals, effective management of comorbidities, follow-up time, diet, and physical activity 6. Therefore, the critical role of HF management programs in improving symptoms and quality of life in both inpatient and outpatient settings has been well recognized and paid continuous attention for the last two decades, with regular updates on team-based healthcare systems and home-based patient care 8,9,10.
Recent updates in treatment guidelines have highlighted the role of the treating physician in customizing and adjusting the therapeutic drugs’ doses, to match those recommended as target or optimal, which must also be well-tolerated by the patients, with the aim of improving clinical outcomes 12. Therefore, it could be deduced that not only the sheer application of the four evidence-based foundational treatment but also dose adjustment over time of each one, should be collectively recognized as the basis of treating patients with HFrEF.
The operation of a highlyspecialized unit, solely dedicated to the management of HF, known as ‘Heart Failure Unit’, has proven its effectiveness, by means of optimization of medical therapy, irrespective of baseline EF, but most notably reduced EF. Therefore, patients’ symptoms and readmission rate in facilities with “Heart Failure Unit” has witnessed a noticeable reduction. In today’s Vietnam, many tertiary medical facilities have implemented such centralized heart failure care models, and the Cardiology Department of Nhan dan Gia Dinh Hospital is definitely not an exception. The Heart Failure Unit in our department has been established and operating with a soulful dedication to providing HF patients with utmost comprehensive care and guideline-recommended therapy.
Tài liệu tham khảo
Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123-1133. doi:10.1016/J.JACC.2013.11.053
Tiller D, Russ M, Greiser KH, et al. Prevalence of Symptomatic Heart Failure with Reduced and with Normal Ejection Fraction in an Elderly General Population–The CARLA Study. PLoS One. 2013;8(3):e59225. doi:10.1371/JOURNAL.PONE.0059225
Abraham WT, Zile MR, Weaver FA, et al. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. JACC Hear Fail. 2015;3(6):487-496. doi: 10.1016/J.JCHF.2015.02.006
Lewis GD, Semigran MJ, Givertz MM, et al. Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. Circ Heart Fail. 2016;9(5). doi: 10.1161/CIRCHEARTFAILURE.115.000345
Crişan S, Petrescu L, Lazăr MA, et al. Reduced ejection fraction heart failure - new data from multicenter studies and national registries regarding general and elderly populations: hopes and disappointments. Clin Interv Aging. 2018;13:651-656. doi: 10.2147/CIA.S161385
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16). doi: 10.1161/CIR.0B013E31829E8776
Cheng A, Ng K. Management programmes for heart failure. Heart. 2004;90(9):972-974. doi: 10.1136/HRT.2003.027375
Chan Y-K, David AM, Mainland C, et al. Applying Heart Failure Management to Improve Health Outcomes: But WHICH One? Card Fail Rev. 2017;3(2):113. doi: 10.15420/CFR.2017:11:1
Moertl D, Altenberger J, Bauer N, et al. Disease management programs in chronic heart failure: Position statement of the Heart Failure Working Group and the Working Group of the Cardiological Assistance and Care Personnel of the Austrian Society of Cardiology. Wien Klin Wochenschr. 2017;129(23-24):869-878. doi: 10.1007/S00508-017-1265-0/TABLES/2
Farwati M, Riaz H, Tang WHW. Digital Health Applications in Heart Failure: a Critical Appraisal of Literature. Curr Treat Options Cardiovasc Med. 2021;23(2):12. doi: 10.1007/S11936-020-00885-Z
J.F Nauta, Santana, Astrid koops. Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. Natherland heart journal, 2021 29(3) doi: 10.1007/s12471-021-01591-6
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18). doi: 10.1161/CIR.0000000000001063
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi: 10.1093/EURHEARTJ/EHAB368.
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureThe Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-2200. doi: 10.1093/EURHEARTJ/EHW128
Maggioni AP, Anker SD, Dahlström U, et al. Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2013;15(10):1173-1184. doi: 10.1093/EURJHF/HFT134
Shah A, Gandhi D, Srivastava S, et al. Heart Failure: A Class Review of Pharmacotherapy. Pharm Ther. 2017;42(7):464. Accessed May 9, 2022. /pmc/articles/PMC5481297/
Krum H. Prospective comparison of ARNi With ACE-I to determine impact on global mortality and morbidity in heart failure (PARADIGM-HF): Paragon of a study or further investigation paramount? Circulation. 2015;131(1):11-12. doi: 10.1161/CIRCULATIONAHA.114.013887
Nassif ME, Windsor S, Tang F, et al. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. Circulation. 2019;140(18). doi: 10.1161/CIRCULATIONAHA.119.042929
Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet (London, England). 2020;396(10254):819-829. doi: 10.1016/S0140-6736(20)31824-9
Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2016;2016(4). doi: 10.1002/14651858.CD003838.PUB4
